文献速递心脑血管急症

临床决策辅助工具与CT冠状动脉造影在疑似急性冠脉综合征患者中的应用

Clinical decision aids and computed tomography coronary angiography in patients with suspected acute coronary syndrome.
PubMed 文献 · Emerg Med J · 2024-07-22
一句话结论在疑似急性冠脉综合征的中危患者中,T-MACS模型联合CT冠状动脉造影对院内诊断急性冠脉综合征和预测30天血运重建的区分度最佳。

该研究为多中心随机对照试验的二次分析,纳入699例接受早期CT冠状动脉造影且数据完整的疑似急性冠脉综合征中危患者,其中358例(51%)院内诊断为急性冠脉综合征。CT冠状动脉造影的C统计量为0.80,高于T-MACS模型(0.78)、HEART评分(0.74)和GRACE评分(0.60);CT冠状动脉造影无冠状动脉病变的阴性预测值为0.90,T-MACS估计值<0.05为0.83,HEART评分<4为0.81,GRACE评分<109为0.55。T-MACS估计值联合CT冠状动脉造影对院内诊断急性冠脉综合征的C统计量为0.88,对30天血运重建为0.85,区分度最佳;T-MACS估计值<0.05且冠状动脉正常的患者院内均无急性冠脉综合征、30天内均未行血运重建。

要点

  • 在699例中危患者中,CT冠状动脉造影对院内诊断急性冠脉综合征的C统计量为0.80,高于T-MACS模型(0.78)、HEART评分(0.74)和GRACE评分(0.60)。
  • CT冠状动脉造影无冠状动脉病变的阴性预测值为0.90,T-MACS估计值<0.05为0.83,HEART评分<4为0.81,GRACE评分<109为0.55。
  • 对30天血运重建,CT冠状动脉造影的C统计量为0.80,无冠状动脉病变和无阻塞性冠状动脉病变的阴性预测值分别为0.96和0.92。
  • T-MACS估计值联合CT冠状动脉造影对院内诊断急性冠脉综合征的C统计量为0.88,对30天血运重建为0.85,区分度最佳。
  • T-MACS估计值<0.05且冠状动脉正常的患者,院内均无急性冠脉综合征,30天内均未行血运重建。

适用人群与场景

  • 疑似急性冠脉综合征的中危患者,接受早期CT冠状动脉造影且数据完整者。

研究设计与关键结果

  • 研究类型:多中心随机对照试验的二次分析,纳入699例接受早期CT冠状动脉造影且数据完整的疑似急性冠脉综合征中危患者,358例(51%)院内诊断为急性冠脉综合征。
  • 院内诊断急性冠脉综合征的C统计量:CT冠状动脉造影0.80,T-MACS模型0.78,HEART评分0.74,GRACE评分0.60。
  • 阴性预测值:CT冠状动脉造影无冠状动脉病变0.90,T-MACS估计值<0.05为0.83,HEART评分<4为0.81,GRACE评分<109为0.55。
  • 30天血运重建:CT冠状动脉造影C统计量0.80,无冠状动脉病变阴性预测值0.96,无阻塞性冠状动脉病变阴性预测值0.92。
  • T-MACS估计值联合CT冠状动脉造影对院内诊断急性冠脉综合征的C统计量为0.88,对30天血运重建为0.85。
  • T-MACS估计值<0.05且冠状动脉正常的患者,院内均无急性冠脉综合征,30天内均未行血运重建。

证据类型、等级与局限

  • 证据类型:多中心随机对照试验的二次分析。
  • 局限:原文未报告局限性。

对床旁实践的改变

  • 在疑似急性冠脉综合征的中危患者中,作者认为T-MACS模型联合CT冠状动脉造影可改善对院内诊断急性冠脉综合征的区分度和对30天血运重建的预测。

提炼说明

  • 本条依据论文摘要整理;摘要未涉及「诊断标准与关键阈值」「处置流程与药物剂量」「红旗征与不能漏的情况」「指南或共识出处」,故未列出这些栏目;全文请点「阅读原文」。
英文原文(摘要)· 点击展开

BACKGROUND: The HEART score, the T-MACS model and the GRACE score support early decision-making for acute chest pain, which could be complemented by CT coronary angiography (CTCA). However, their performance has not been directly compared.

METHODS: In this secondary analysis of a multicentre randomised controlled trial of early CTCA in intermediate-risk patients with suspected acute coronary syndrome, C-statistics and performance metrics (using the predefined cut-offs) of clinical decision aids and CTCA, alone and then in combination, for the index hospital diagnosis of acute coronary syndrome and for 30-day coronary revascularisation were assessed in those who underwent CTCA and had complete data.

RESULTS: Among 699 patients, 358 (51%) had an index hospital diagnosis of acute coronary syndrome, for which the C-statistic was higher for CTCA (0.80), followed by the T-MACS model (0.78), the HEART score (0.74) and the GRACE score (0.60). The negative predictive value was higher for the absence of coronary artery disease on CTCA (0.90) or a T-MACS estimate of <0.05 (0.83) than a HEART score of <4 (0.81) and a GRACE score of <109 (0.55). For 30-day coronary revascularisation, CTCA had the greatest C-statistic (0.80) with a negative predictive value of 0.96 and 0.92 in the absence of coronary artery disease and obstructive coronary artery disease, respectively. The combination of the T-MACS estimates and the CTCA findings was most discriminative for the index hospital diagnosis of acute coronary syndrome (C-statistic, 0.88) and predictive of 30-day coronary revascularisation (C-statistic, 0.85). No patients with a T-MACS estimate of <0.05 and normal coronary arteries had acute coronary syndrome during index hospitalisation or underwent coronary revascularisation within 30 days.

CONCLUSIONS: In intermediate-risk patients with suspected acute coronary syndrome, the T-MACS model combined with CTCA improved discrimination of the index hospital diagnosis of acute coronary syndrome and prediction of 30-day coronary revascularisation.

TRIAL REGISTRATION NUMBER: NCT02284191.

来源:Emerg Med J,查看原文。版权归原作者所有。

参考来源

  1. Wang KL, Taggart C, McDermott M, et al. Clinical decision aids and computed tomography coronary angiography in patients with suspected acute coronary syndrome. Emerg Med J. 2024. PMID: 38857986. doi:10.1136/emermed-2024-213904

供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。